Cosmetic peptides
Cosmetic peptides are formulated for topical use in skin and hair products rather than systemic administration. The category includes SNARE-targeting sequences marketed for expression lines, copper-binding tripeptides, and signal peptides used in collagen research. Systemic pharmacokinetics is usually not established because these are not intended to be absorbed.
26 profiles in this category. Browse all peptides. Research use only. Not medical advice.
Cosmetic peptides (26)
Cosmetic • Cosmetic SNARE-targeting peptide • Experimental
Topical hexapeptide (Argireline) used in cosmetics as a SNAP-25 fragment analog. Marketed to soften expression lines; not an FDA-approved drug.
Mechanism: Acetyl hexapeptide-8, commonly sold as Argireline, mimics…
Half-life: Topical; systemic PK not established
MW: —
Cosmetic • Cosmetic SNARE-targeting peptide • Experimental
Elongated Argireline analog (SNAP-8) used in topical cosmetics. Not an FDA-approved drug; not WADA-prohibited as a cosmetic peptide.
Mechanism: Acetyl octapeptide-3, sold as SNAP-8, is an elongated ana…
Half-life: Topical; systemic PK not established
MW: ≈1075.2 g/mol
Cosmetic • Cosmetic hair and skin matrikine • Experimental
Short acetylated tetrapeptide used topically in hair-density and skin-firmness formulations, commonly paired with red clover extract in commercial blends. Regulated as a cosmetic ingredient, not FDA-approved as a drug.
Mechanism: Acetyl tetrapeptide-3 is described as a matrikine — a pep…
MW: 509.6 g/mol
Cosmetic • FDA-approved α-MSH analog • Established
FDA-approved α-MSH analog implant (SCENESSE) to increase pain-free light exposure in adults with erythropoietic protoporphyria. 16 mg subcutaneous implant every 2 months.
Mechanism: Afamelanotide is a synthetic analog of alpha-melanocyte-s…
Half-life: ~30 minutes (plasma); ~15 h (from implant)
MW: 1646.9 g/mol
Cosmetic • Copper tripeptide / cosmetic research • Experimental
Alanine-histidine-lysine copper complex used in hair- and skin-cosmetic research, related to GHK-Cu. Not an FDA-approved drug.
Mechanism: AHK-Cu is the copper complex of the tripeptide alanyl-his…
MW: 451.39 g/mol
Cosmetic • Cosmetic hair peptide • Experimental
Biotin-conjugated tripeptide used in topical hair and lash products, typically as part of proprietary blends. Not FDA-approved as a drug; regulated as a cosmetic ingredient.
Mechanism: The peptide couples biotin to the GHK tripeptide, which h…
MW: 566.7 g/mol
Cosmetic • Cosmetic tyrosinase-inhibiting peptide • Experimental
Synthetic decapeptide used topically in pigmentation products as a non-hydroquinone alternative. Regulated as a cosmetic ingredient; not FDA-approved as a drug.
Mechanism: Decapeptide-12 was identified by screening for peptides t…
MW: 1395.5 g/mol
Cosmetic • Cosmetic nicotinic antagonist mimetic • Experimental
Waglerin-1–inspired tripeptide used in cosmetics to reduce expression-line appearance. Topical cosmetic active, not an FDA drug.
Mechanism: This dipeptide is a synthetic mimetic of waglerin-1, a co…
Half-life: Topical; systemic PK not established
MW: —
Muscle/Recovery • Copper tripeptide / cosmetic and research • Experimental
Endogenous glycyl-L-histidyl-L-lysine copper complex used widely in cosmetics for skin remodeling. Injectable research use is unapproved. USADA lists GHK (tripeptide-1) as not prohibited.
Mechanism: GHK is a naturally occurring tripeptide (glycyl-L-histidy…
Half-life: Short; typically used topically
MW: 403.92 g/mol
Muscle/Recovery • Regenerative-cosmetic blend • Experimental
Vendor blend typically combining GHK-Cu, BPC-157, and TB-500 for cosmetic/regenerative research. Not a single API; BPC-157 and TB-500 are WADA issues if the blend contains them.
Mechanism: Glow is a compounded blend rather than a single compound,…
Half-life: Varies by component
MW: Varies
Longevity • Endogenous tripeptide antioxidant • Experimental
Endogenous antioxidant tripeptide sold as an oral supplement and used IV in clinics. Not FDA-approved as a standalone drug for systemic “detox” or skin-lightening claims.
Mechanism: Glutathione is a tripeptide of glutamate, cysteine and gl…
Half-life: ~1.5 hours (IV); oral bioavailability limited
MW: 307.32 g/mol
Muscle/Recovery • Regenerative blend • Experimental
Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved.
Mechanism: KLOW is a compounded blend of GHK-Cu, KPV, BPC-157 and TB…
Half-life: Varies
MW: Varies
Cosmetic • Anti-inflammatory MSH fragment / research • Experimental
C-terminal α-MSH tripeptide with anti-inflammatory activity in gut and skin models without strong melanotropic tanning. Not FDA-approved.
Mechanism: KPV is Lys-Pro-Val, the C-terminal tripeptide of alpha-me…
Half-life: Short; topical and research injectable use
MW: 342.44 g/mol
Cosmetic • Human cathelicidin / research • Experimental
Human host-defense peptide (cathelicidin) with antimicrobial and immunomodulatory activity. Not FDA-approved as a drug; excess LL-37 is implicated in rosacea/psoriasis biology.
Mechanism: LL-37 is the only human cathelicidin, released by proteol…
Half-life: ~1-2 hours
MW: 4493 Da
Cosmetic • Unapproved melanocortin agonist • Experimental
Cyclic α-MSH analog used illicitly for tanning and libido. Not FDA-approved. FDA and EMA have warned against its use. WADA S0 as a non-approved substance.
Mechanism: Melanotan II is a cyclic lactam analog of alpha-melanocyt…
Half-life: ~36 hours
MW: 1024.2 g/mol
Cosmetic • Cosmetic lash and brow peptide • Experimental
Lipidated pentapeptide used in eyelash and eyebrow conditioning products. Regulated as a cosmetic ingredient; not FDA-approved as a drug and not equivalent to prostaglandin analog lash treatments.
Mechanism: Attachment of a myristoyl fatty acid chain increases lipo…
MW: 796.1 g/mol
Cosmetic • Cosmetic matrikine • Experimental
Palmitoylated hexapeptide used in topical anti-ageing formulations, frequently combined with other matrikines. Regulated as a cosmetic ingredient; not FDA-approved as a drug.
Mechanism: The peptide portion corresponds to a repeating motif of e…
MW: 737 g/mol
Cosmetic • Cosmetic matrikine • Experimental
Palmitoylated KTTKS matrikine (Matrixyl) used in anti-wrinkle cosmetics. Not an FDA drug. Not WADA-prohibited as a cosmetic peptide.
Mechanism: Palmitoyl pentapeptide-4 is the KTTKS sequence, a fragmen…
Half-life: Topical; systemic PK not established
MW: ≈802.07 g/mol
Cosmetic • Cosmetic matrikine • Experimental
Palmitoylated GQPR tetrapeptide used to reduce IL-6 in stressed skin models and paired with pal-tripeptide-1 in Matrixyl 3000.
Mechanism: Palmitoyl tetrapeptide-7 is a short peptide with a palmit…
Half-life: Topical; systemic PK not established
MW: ≈694.9 g/mol
Cosmetic • Cosmetic copper-free GHK analog • Experimental
The GHK tripeptide supplied with a palmitic acid chain attached to improve penetration through the outer skin barrier, and without the bound copper of GHK-Cu. It is used topically as a matrikine, a peptide fragment that signals matrix turnover to dermal fibroblasts, and is most often formulated alongside palmitoyl tetrapeptide-7. Regulated as a cosmetic ingredient rather than a drug, and not FDA-approved for any therapeutic use.
Mechanism: Palmitoyl tripeptide-1 delivers the GHK sequence with a s…
Half-life: Topical; systemic PK not established
MW: ≈578.8 g/mol
Cosmetic • Cosmetic TGF-β mimetic tripeptide • Experimental
Lipidated tripeptide marketed under the Syn-Coll name and used topically in firming and anti-ageing formulations. It is described as a thrombospondin-1 mimetic, intended to promote activation of transforming growth factor beta already present in the dermis rather than to supply new growth factor. Evidence comes predominantly from supplier research and small cosmetic studies. A cosmetic active, not a drug, and not FDA-approved.
Mechanism: Palmitoyl tripeptide-5 is a lipidated tripeptide used top…
Half-life: Topical; systemic PK not established
MW: —
Cosmetic • Hair-follicle Wnt research peptide • Experimental
Cell-penetrating peptide designed to block CXXC5–Dishevelled binding and enhance Wnt signaling in hair-growth mouse models. Not FDA-approved.
Mechanism: PTD-DBM is a fusion of a protein transduction domain, whi…
MW: 3082.6 g/mol
Cosmetic • Cosmetic EGF / research • Experimental
Recombinant or fragment EGF used in cosmetics as sh-oligopeptide-1. Topical cosmetic; injectable EGF is a different, unapproved proposition.
Mechanism: Human epidermal growth factor is a 53-amino-acid protein …
Half-life: Topical; systemic PK not applicable
MW: ≈6.2 kDa (protein growth factor)
Muscle/Recovery • Actin-sequestering peptide / research • Experimental
43-aa G-actin-sequestering peptide studied for wound healing and cardiac repair (timbetasin programs). Not FDA-approved. Distinct from the shorter TB-500 fragment.
Mechanism: Thymosin beta-4 is a 43-amino-acid peptide and the princi…
Half-life: Not well established in humans
MW: ≈4963 g/mol
Cosmetic • Cosmetic firming peptide • Experimental
Fluorinated tripeptide marketed in topical firming products, sold commercially under the Progeline name. Regulated as a cosmetic ingredient; not FDA-approved as a drug.
Mechanism: Supplier research describes inhibition of progerin, a tru…
MW: 475.5 g/mol
Cosmetic • Zinc-bound thymic nonapeptide / research • Experimental
Zinc-complexed form of thymulin, the thymic nonapeptide that requires bound zinc for biological activity. Investigated for immune modulation and, topically, for hair growth. Not FDA-approved.
Mechanism: Thymulin is biologically inactive without a bound zinc io…